<DOC>
	<DOC>NCT01105117</DOC>
	<brief_summary>This is an open-label, non-randomized extension to study AC-066A401. The study will assess safety and tolerability of ACT-385781A and Flolan (epoprostenol sodium) while providing a means for continuing treatment after ending participation in study AC-0066A401.</brief_summary>
	<brief_title>Epoprostenol for Injection in Pulmonary Arterial Hypertension - Extension of AC-066A401</brief_title>
	<detailed_description />
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Familial Primary Pulmonary Hypertension</mesh_term>
	<mesh_term>Epoprostenol</mesh_term>
	<mesh_term>Tezosentan</mesh_term>
	<criteria>1. Signed informed consent prior to initiation of any studymandated procedure 2. Patients who completed participation in study AC066A401 3. Patients who have not obtained authorization for commercial ACT385781 and Flolan at the time of ending participation in study AC066A401 1. Patients who prematurely discontinued study drug in study AC066A401 2. Patients for whom continued treatment with either ACT385781 and Flolan is no longer considered appropriate 3. Known hypersensitivity to the investigational drug or comparative drug or drugs of the same class, or any of their excipients 4. Any known factor or disease that might interfere with treatment compliance, study conduct or interpretation of the results such as drug or alcohol dependence or psychiatric disease 5. Known concomitant lifethreatening disease with a life expectancy &lt; 12 months</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>November 2012</verification_date>
	<keyword>Pulmonary Arterial Hypertension</keyword>
	<keyword>PAH</keyword>
	<keyword>EPITOME-1</keyword>
</DOC>